Surrozen (SRZN) Long-Term Investments (2021 - 2022)
Surrozen (SRZN) posted quarterly Long-Term Investments of $11.8 million for Q1 2022, down 87.2% year-over-year from $92.0 million in Q1 2021, and down 45.6% quarter-over-quarter from $21.7 million in Q4 2021.
Powered by 
Analysis
Surrozen (SRZN) Long-Term Investments (2021 - 2022) Analysis & Trends
Surrozen's Long-Term Investments history runs 2 years deep, the most recent figure standing at $11.8 million for Q1 2022.
- In Q1 2022, Long-Term Investments fell 87.2% year-over-year to $11.8 million; the TTM figure through Mar 2022 stood at $11.8 million (down 87.2% YoY), while the FY2021 annual figure was $21.7 million, changed N/A from the prior year.
- Long-Term Investments for Q1 2022 stood at $11.8 million, down from $21.7 million in the prior quarter.
- The five-year high for Long-Term Investments was $92.0 million in Q2 2021, with the low at $11.8 million in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Surrozen | 263.35 Mn | 263.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 11.78 Mn |
| Dec 31, 2021 | 21.66 Mn |
| Sep 30, 2021 | 25.26 Mn |
| Jun 30, 2021 | 92.03 Mn |
| Mar 31, 2021 | 92.03 Mn |